363 related articles for article (PubMed ID: 34697627)
1. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months.
Ponticelli D; Antonazzo IC; Caci G; Vitale A; Della Ragione G; Romano ML; Borrelli M; Schiavone B; Polosa R; Ferrara P
J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34697627
[No Abstract] [Full Text] [Related]
2. Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals.
Al-Sadeq DW; Shurrab FM; Ismail A; Amanullah FH; Thomas S; Aldewik N; Yassine HM; Abdul Rahim HF; Abu-Raddad L; Nasrallah GK
J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34888670
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
Olariu TR; Ursoniu S; Marincu I; Lupu MA
Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
[No Abstract] [Full Text] [Related]
4. Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine.
Gobbi F; Buonfrate D; Silva R; Martini D; Bisoffi Z; Piubelli C; Riccetti S; Sinigaglia A; Barzon L
J Infect; 2022 Jan; 84(1):94-118. PubMed ID: 34371075
[No Abstract] [Full Text] [Related]
5. Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi GL; Lippi G
Clin Chem Lab Med; 2021 Sep; 59(10):e377-e379. PubMed ID: 34162025
[No Abstract] [Full Text] [Related]
6. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
Front Immunol; 2021; 12():752233. PubMed ID: 34899701
[TBL] [Abstract][Full Text] [Related]
7. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
9. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
[No Abstract] [Full Text] [Related]
10. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
Herishanu Y; Avivi I; Levi S; Shefer G; Bronstein Y; Moshiashvili MM; Ziv T; Scarfò L; Perry C; Ghia P
Blood Adv; 2022 Jan; 6(1):148-151. PubMed ID: 34614513
[No Abstract] [Full Text] [Related]
11. Comparison of antibody response to two different mRNA Covid-19 vaccines in patients on hemodialysis.
Ionita C; Marcelli D; Nita C; Anton C; Berca S; Vacar S; Schiller O; Gheorghiu C; Barth C
J Nephrol; 2022 Jan; 35(1):143-151. PubMed ID: 34978050
[TBL] [Abstract][Full Text] [Related]
12. Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.
Chammartin F; Kusejko K; Pasin C; Trkola A; Briel M; Amico P; Stoekle MP; Eichenberger AL; Hasse B; Braun DL; Schuurmans MM; Müller TF; Tamm M; Mueller NJ; Rauch A; Koller MT; Günthard HF; Bucher HC; Speich B; Abela IA;
AIDS; 2022 Aug; 36(10):1465-1468. PubMed ID: 35876706
[TBL] [Abstract][Full Text] [Related]
13. BNT162B2 mRNA COVID-19 Vaccine in Heart and Lung Transplanted Young Adults: Is an Alternative SARS-CoV-2 Immune Response Surveillance Needed?
Cotugno N; Pighi C; Morrocchi E; Ruggiero A; Amodio D; Medri C; Colagrossi L; Russo C; Di Cesare S; Santilli V; Manno EC; Zangari P; Giancotta C; Bernardi S; Nicolosi L; Ciofi Degli Atti M; Raponi M; Zaffina S; Alfieri S; Kirk R; Perno CF; Rossi P; Amodeo A; Palma P
Transplantation; 2022 Feb; 106(2):e158-e160. PubMed ID: 34954734
[No Abstract] [Full Text] [Related]
14. Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study.
Buonfrate D; Piubelli C; Gobbi F; Martini D; Bertoli G; Ursini T; Moro L; Ronzoni N; Angheben A; Rodari P; Cardellino C; Tamarozzi F; Tais S; Rizzi E; Degani M; Deiana M; Prato M; Silva R; Bisoffi Z
Clin Microbiol Infect; 2021 Dec; 27(12):1845-1850. PubMed ID: 34329793
[TBL] [Abstract][Full Text] [Related]
15. Viral-like Reaction or Hypersensitivity? Erythema Multiforme Minor Reaction and Moderate Eosinophilia After the Pfizer-BioNTech BNT162b2 (mRNA-Based) SARS-CoV-2 Vaccine.
de Las Vecillas L; López J; Morchón E; Rodriguez F; Drake M; Martino M
J Investig Allergol Clin Immunol; 2021 Feb; 32(1):77-78. PubMed ID: 34588156
[No Abstract] [Full Text] [Related]
16. A case of sensory ataxic Guillain-Barré syndrome with immunoglobulin G anti-GM1 antibodies following the first dose of mRNA COVID-19 vaccine BNT162b2 (Pfizer).
Fukushima T; Tomita M; Ikeda S; Hattori N
QJM; 2022 Jan; 115(1):25-27. PubMed ID: 34871447
[No Abstract] [Full Text] [Related]
17. High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
Gianserra L; Donà MG; Giuliani E; Stingone C; Pontone M; Buonomini AR; Giuliani M; Pimpinelli F; Morrone A; Latini A
AIDS; 2022 Jul; 36(9):1319-1320. PubMed ID: 35833685
[No Abstract] [Full Text] [Related]
18. Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies.
Ferrara P; Ponticelli D; Agüero F; Caci G; Vitale A; Borrelli M; Schiavone B; Antonazzo IC; Mantovani LG; Tomaselli V; Polosa R
Public Health; 2022 Feb; 203():97-99. PubMed ID: 35038631
[TBL] [Abstract][Full Text] [Related]
19. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
Front Immunol; 2021; 12():778679. PubMed ID: 34868051
[TBL] [Abstract][Full Text] [Related]
20. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
